Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build

TheFly reported connected January 9 that Stifel accrued its terms people connected GH to $120 from $100 portion maintaining a Buy rating. The steadfast anticipates beardown measurement and mean selling terms maturation successful 2026, with work and reimbursement events that it claims volition support investors interested.

Similarly, connected the aforesaid day, Mizuho raised its terms people connected Guardant Health, Inc. (NASDAQ:GH) to $135 from $120 portion maintaining an Outperform rating. Additionally, the steadfast revised its models for the diagnostics and aesculapian instrumentality sectors.

Guardant Health, Inc. (NASDAQ:GH) is simply a precision oncology institution focused connected processing non-invasive liquid biopsy tests for crab detection, attraction selection, and illness monitoring. Its flagship products, including Guardant360 and Guardant Shield, alteration aboriginal detection, biomarker profiling, and real-time monitoring, supporting personalized crab care.

While we admit the imaginable of GH arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.